These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22111969)

  • 1. Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.
    Johnsen HE; Haioun C; Lugtenburg PJ; Salar A; Jaeger U; Pettengell R; Rossi FG; Verhoef G; Schwenkglenks M; Bendall K; Duehrsen U
    Leuk Lymphoma; 2012 May; 53(5):982-4. PubMed ID: 22111969
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
    Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fourteen-day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP-14): use it right or do not use it at all.
    Zwick C; Pfreundschuh M
    Leuk Lymphoma; 2012 May; 53(5):758-9. PubMed ID: 22263568
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
    Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
    Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
    Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
    Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.
    Kasahara S; Hara T; Tsurumi H; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Goto H; Fukuno K; Yamada T; Sawada M; Takahashi T; Takami T; Moriwaki H
    Leuk Lymphoma; 2011 Apr; 52(4):629-34. PubMed ID: 21438831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.
    Hong J; Park S; Park J; Kim HS; Kim KH; Ahn JY; Rim MY; Jung M; Sym SJ; Cho EK; Shin DB; Lee JH
    Leuk Lymphoma; 2011 Oct; 52(10):1904-12. PubMed ID: 21718130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of diffuse large B-cell lymphoma in the rituximab era].
    Kinoshita T
    Rinsho Ketsueki; 2009 Oct; 50(10):1342-50. PubMed ID: 19915341
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid.
    Jonak C; Troch M; Müllauer L; Niederle B; Hoffmann M; Raderer M
    Thyroid; 2010 Apr; 20(4):425-7. PubMed ID: 20210673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America.
    Beltran BE; Castillo JJ; Salas R; Quiñones P; Morales D; Cotrina E; Miranda RN; Sotomayor EM
    Leuk Lymphoma; 2011 Jan; 52(1):153-6. PubMed ID: 21219127
    [No Abstract]   [Full Text] [Related]  

  • 17. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
    Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
    Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab.
    Cheng C; Gallagher EM; Yeh JY; Earl MA
    Anticancer Drugs; 2014 Sep; 25(8):964-9. PubMed ID: 24743519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal positron emission tomography (PET) scan secondary to the use of hematopoietic growth factors.
    Johnston KL; Farnen JP; Manske BR; Go RS
    Haematologica; 2005 Dec; 90(12 Suppl):EIM03. PubMed ID: 16464762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.